[INSERT YOUR ADDRESS
+ POSTCODE]

**URGENT: TRANSPARENCY REGARDING THE PROCUREMENT OF EVUSHELD – PREVENTATIVE COVID-19 TREATMENT**

Dear [INSERT NAME OF MP],

My name is [INSERT YOUR NAME] and I am a constituent of [INSERT YOUR CONSTITUENCY]. I am writing to you because I am concerned about the Government’s decision-making process around Evusheld, a prophylactic (preventative) drug approved by the MHRA that protects against Covid-19. It has the potential to be the most important pharmaceutical intervention for immunocompromised people since the start of the pandemic, for whom [vaccines aren’t always as effective](https://bloodcancer.org.uk/support-for-you/coronavirus-covid-19/covid-vaccine-blood-cancer/covid-vaccine-efficacy-blood-cancer/).

Many immunocompromised people like [ME / MY LOVED ONE], who has [CONDITION NAME], are still shielding after two years because we are at disproportionate risk of dying from Covid. Evusheld therefore offers a vital way for immunocompromised people to be protected and to lower risk levels and begin to ‘live with Covid’ as the rest of the population has.

On 12 August 2022, the Department of Health announced that the Government will not decide whether to procure Evusheld until an appraisal is completed by the National Institute for Health and Care Excellence (NICE) in April 2023. Evusheld, however, is being monitored as part of the RAPID C-19 initiative. Other Covid treatments monitored by RAPID C-19 were procured and made available before a NICE appraisal. There is a wealth of robust evidence demonstrating Evusheld’s effectiveness at preventing Covid-19 infection, and of reducing severity of illness.

This decision has been made in such a way as to preclude scrutiny from the public. The Department of Health has not explained its reasoning for making this decision, it has not published a report of its review of the available evidence, and it has not published any documentation evidencing consultation with clinical experts. I am deeply concerned by the lack of transparency involved in this decision-making process.

To address these concerns, **please can you write to the Secretary of State on my behalf?** I ask you to urge him to publish the following:

* The clinicians consulted in advance of this decision
* The analysis of the clinical evidence used to make this decision
* A statement outlining, in detail, the Department’s reasoning for this decision

This is an urgent matter. A preventative drug like Evusheld could dramatically change the lives of immunocompromised people in the UK. I look forward to hearing from you as soon as possible.

Yours sincerely,

[YOUR NAME]